- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
Five More Companies Join NIH's Drug Reuse Program
12 June 2012 2:20 pm
The National Institutes of Health (NIH) today unveiled the details of its $20 million program for finding new uses for abandoned drugs—along with five more participating companies. The program's expansion brings to 58 the number of shelved compounds that academic researchers can test for new uses.
Discovering New Therapeutic Uses for Existing Molecules, announced in early May, is the first major initiative from NIH's new National Center for Advancing Translational Science (NCATS). The idea is to give academic researchers access to compounds that made it through safety testing but were dropped by companies for business reasons or because they didn't work on a specific disease. Initially, three companies—Pfizer, AstraZeneca, and Eli Lilly—offered to share 24 compounds.
Now Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, and Janssen Pharmaceuticals have signed on, bringing the number of compounds to 58. NIH has posted a table of the compounds that links to one-page fact sheets about the drugs that include the mechanism of action and summary clinical results. NIH is also taking preapplications (due 14 August) for the program's 2- to 3-year grants.
The program has gotten a mixed response from pharma experts; some think the chances of finding new uses for the compounds are slim. Others are supportive but have concerns about the template legal agreements NIH has developed for companies and academics. In this 1 June letter to NCATS, the Association of American Medical Colleges says the templates should be revised because they "require academic partners to share data and other information with firms providing the compounds even where IP [intellectual property] rights do not necessarily extend to that information."